We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Alphabet, AbbVie, Qualcomm and Flanigan's
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 14, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , AbbVie Inc. (ABBV - Free Report) , Qualcomm Inc. (QCOM - Free Report) , and Flanigan's Enterprises, Inc. (BDL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Alphabet, AbbVie and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., AbbVie Inc. and Qualcomm Inc., as well as a micro-cap stock Flanigan's Enterprises, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Alphabet shares have been hit hard in the recent market turmoil, with the stock lagging the Mag 7 group as well as the Zacks Tech sector and the S&P 500 index since mid-July 2024. The immediate catalyst for the sell-off was Alphabet's July 23rd Q2 earnings report when it beat on the top- and bottom-lines but failed to satisfy investors with its ever-rising capex spending levels.
The Zacks analyst sees the market's capex fixation as over-done and strongly argues that Alphabet's aggressive spending plans are essential to its status as a leader in the coming AI world.
The company remains a leader in the search space and AI investments are critical to it sustaining that lead.
Well-performing Google Cloud remains the key catalyst. Expanding data centers and growing generative AI capabilities remain major positives for cloud business. Also, integration of generative AI into the company's search engine is expected to sustain its dominance in the search market.
Strong efforts to gain a foothold in the healthcare industry are other positives. Deepening focus on wearables category and autonomous driving space, is a plus. However, sluggishness in the company's Network advertisement business is a concern. Growing litigation issues and increasing expenses are headwinds.
Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+22.7% vs. +21.1%). The company has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq.
Skyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, which should support top-line growth in the next few years AbbVie has several early/mid-stage candidates that have potential to drive long-term growth. Boosted by its new product launches, AbbVie expects to return to robust revenue growth in 2025.
However, the company faces several near-term headwinds like Humira's biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth trend for fillers in the United States and China.
Qualcomm's shares have outperformed the Zacks Wireless Equipment industry over the past year (+42.8% vs. +40.0%). The company reported strong third-quarter fiscal 2024 results, with the bottom and top lines beating the respective Zacks Consensus Estimate, driven by healthy demand trends in Android handsets and record automotive revenues.
The Snapdragon X Series Platform integrated with Qualcomm AI Hub is witnessing significant market traction among leading global PC manufacturers. The company is increasingly focusing on the seamless transition from a wireless communications firm for the mobile industry to a connected processor firm for the intelligent edge and has offered bullish guidance for the fourth quarter.
However, inventory corrections by clients are impeding sales in the IoT business. Increasing competition in the mobile phone chipset market is likely to strain margins. Rising geopolitical instability and high debt obligation remain concerns.
Shares of Flanigan's have declined -0.3% over the year-to-date period against the Zacks Retail - Restaurants industry's decline of -7.2%. This microcap company with market capitalization of $47.73 million maintains a strong revenue growth, effective cost management, positive cash flow and a solid financial position. New store openings and operational improvements, like NetSuite, bode well.
Yet, Flanigan's net income fell 18.6% in first-quarter 2024 despite a 9.7% revenue uptick, highlighting rising costs and potential inefficiencies. Operating expenses rose 10.4%, driven by higher payroll, consultant fees, and food costs, eroding profit margins. High long-term debt poses a financial risk, especially if interest rates rise.
Franchise-related revenues fell 8.5%, indicating possible operational issues. Declining gross profit margins for restaurant and package store sales signal higher costs without matching price increases. Competitive pressures, economic sensitivity and substantial lease obligations also challenge profitability.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Alphabet, AbbVie, Qualcomm and Flanigan's
For Immediate Release
Chicago, IL – August 14, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , AbbVie Inc. (ABBV - Free Report) , Qualcomm Inc. (QCOM - Free Report) , and Flanigan's Enterprises, Inc. (BDL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Alphabet, AbbVie and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., AbbVie Inc. and Qualcomm Inc., as well as a micro-cap stock Flanigan's Enterprises, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Alphabet shares have been hit hard in the recent market turmoil, with the stock lagging the Mag 7 group as well as the Zacks Tech sector and the S&P 500 index since mid-July 2024. The immediate catalyst for the sell-off was Alphabet's July 23rd Q2 earnings report when it beat on the top- and bottom-lines but failed to satisfy investors with its ever-rising capex spending levels.
The Zacks analyst sees the market's capex fixation as over-done and strongly argues that Alphabet's aggressive spending plans are essential to its status as a leader in the coming AI world.
The company remains a leader in the search space and AI investments are critical to it sustaining that lead.
Well-performing Google Cloud remains the key catalyst. Expanding data centers and growing generative AI capabilities remain major positives for cloud business. Also, integration of generative AI into the company's search engine is expected to sustain its dominance in the search market.
Strong efforts to gain a foothold in the healthcare industry are other positives. Deepening focus on wearables category and autonomous driving space, is a plus. However, sluggishness in the company's Network advertisement business is a concern. Growing litigation issues and increasing expenses are headwinds.
(You can read the full research report on Alphabet here >>>)
Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+22.7% vs. +21.1%). The company has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq.
Skyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, which should support top-line growth in the next few years AbbVie has several early/mid-stage candidates that have potential to drive long-term growth. Boosted by its new product launches, AbbVie expects to return to robust revenue growth in 2025.
However, the company faces several near-term headwinds like Humira's biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth trend for fillers in the United States and China.
(You can read the full research report on AbbVie here >>>)
Qualcomm's shares have outperformed the Zacks Wireless Equipment industry over the past year (+42.8% vs. +40.0%). The company reported strong third-quarter fiscal 2024 results, with the bottom and top lines beating the respective Zacks Consensus Estimate, driven by healthy demand trends in Android handsets and record automotive revenues.
The Snapdragon X Series Platform integrated with Qualcomm AI Hub is witnessing significant market traction among leading global PC manufacturers. The company is increasingly focusing on the seamless transition from a wireless communications firm for the mobile industry to a connected processor firm for the intelligent edge and has offered bullish guidance for the fourth quarter.
However, inventory corrections by clients are impeding sales in the IoT business. Increasing competition in the mobile phone chipset market is likely to strain margins. Rising geopolitical instability and high debt obligation remain concerns.
(You can read the full research report on QUALCOMM here >>>)
Shares of Flanigan's have declined -0.3% over the year-to-date period against the Zacks Retail - Restaurants industry's decline of -7.2%. This microcap company with market capitalization of $47.73 million maintains a strong revenue growth, effective cost management, positive cash flow and a solid financial position. New store openings and operational improvements, like NetSuite, bode well.
Yet, Flanigan's net income fell 18.6% in first-quarter 2024 despite a 9.7% revenue uptick, highlighting rising costs and potential inefficiencies. Operating expenses rose 10.4%, driven by higher payroll, consultant fees, and food costs, eroding profit margins. High long-term debt poses a financial risk, especially if interest rates rise.
Franchise-related revenues fell 8.5%, indicating possible operational issues. Declining gross profit margins for restaurant and package store sales signal higher costs without matching price increases. Competitive pressures, economic sensitivity and substantial lease obligations also challenge profitability.
(You can read the full research report on Flanigan's here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.